vs
BCB BANCORP INC（BCBP）与STANDARD BIOTOOLS INC.（LAB）财务数据对比。点击上方公司名可切换其他公司
BCB BANCORP INC的季度营收约是STANDARD BIOTOOLS INC.的1.3倍（$26.2M vs $19.6M），BCB BANCORP INC净利率更高（-49.7% vs -177.4%，领先127.7%），BCB BANCORP INC同比增速更快（13.1% vs -11.5%），BCB BANCORP INC自由现金流更多（$34.9M vs $-23.1M），过去两年BCB BANCORP INC的营收复合增速更高（1.8% vs -12.2%）
Standard BioTools（原Fluidigm公司）是一家美国生命科学工具企业，主营流式细胞术与组织成像分析用质谱流式系统，以及配套的检测试剂盒与试剂，同时供应自动化基因组分析仪器、各类微流控芯片（又称集成流体电路）及配套试剂耗材，全系列产品及应用场景均可提供定制检测方案与相关服务。
BCBP vs LAB — 直观对比
营收规模更大
BCBP
是对方的1.3倍
$19.6M
营收增速更快
BCBP
高出24.6%
-11.5%
净利率更高
BCBP
高出127.7%
-177.4%
自由现金流更多
BCBP
多$58.0M
$-23.1M
两年增速更快
BCBP
近两年复合增速
-12.2%
损益表 — Q4 FY2025 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $26.2M | $19.6M |
| 净利润 | $-12.0M | $-34.7M |
| 毛利率 | — | 48.5% |
| 营业利润率 | -71.9% | -168.5% |
| 净利率 | -49.7% | -177.4% |
| 营收同比 | 13.1% | -11.5% |
| 净利润同比 | -467.6% | -28.8% |
| 每股收益（稀释后） | $-0.73 | $-0.09 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BCBPLAB
| Q4 25 | $26.2M | — | ||
| Q3 25 | $26.5M | $19.6M | ||
| Q2 25 | $25.2M | $21.8M | ||
| Q1 25 | $23.8M | $40.8M | ||
| Q4 24 | $23.1M | — | ||
| Q3 24 | $26.2M | $22.1M | ||
| Q2 24 | $20.4M | $22.5M | ||
| Q1 24 | $25.3M | $45.5M |
净利润BCBPLAB
| Q4 25 | $-12.0M | — | ||
| Q3 25 | $4.3M | $-34.7M | ||
| Q2 25 | $3.6M | $-33.5M | ||
| Q1 25 | $-8.3M | $-26.0M | ||
| Q4 24 | $3.3M | — | ||
| Q3 24 | $6.7M | $-26.9M | ||
| Q2 24 | $2.8M | $-45.7M | ||
| Q1 24 | $5.9M | $-32.2M |
毛利率BCBPLAB
| Q4 25 | — | — | ||
| Q3 25 | — | 48.5% | ||
| Q2 25 | — | 48.8% | ||
| Q1 25 | — | 48.4% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 54.9% | ||
| Q2 24 | — | 46.1% | ||
| Q1 24 | — | 53.1% |
营业利润率BCBPLAB
| Q4 25 | -71.9% | — | ||
| Q3 25 | 21.9% | -168.5% | ||
| Q2 25 | 19.9% | -118.1% | ||
| Q1 25 | -49.2% | -80.8% | ||
| Q4 24 | 19.9% | — | ||
| Q3 24 | 35.7% | -120.9% | ||
| Q2 24 | 19.5% | -134.5% | ||
| Q1 24 | 33.0% | -132.2% |
净利率BCBPLAB
| Q4 25 | -49.7% | — | ||
| Q3 25 | 16.1% | -177.4% | ||
| Q2 25 | 14.2% | -153.7% | ||
| Q1 25 | -35.0% | -63.8% | ||
| Q4 24 | 14.1% | — | ||
| Q3 24 | 25.5% | -122.0% | ||
| Q2 24 | 13.8% | -203.3% | ||
| Q1 24 | 23.2% | -70.6% |
每股收益（稀释后）BCBPLAB
| Q4 25 | $-0.73 | — | ||
| Q3 25 | $0.22 | $-0.09 | ||
| Q2 25 | $0.18 | $-0.09 | ||
| Q1 25 | $-0.51 | $-0.07 | ||
| Q4 24 | $0.17 | — | ||
| Q3 24 | $0.36 | $-0.07 | ||
| Q2 24 | $0.14 | $-0.12 | ||
| Q1 24 | $0.32 | $-0.27 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $129.4M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $304.3M | $399.7M |
| 总资产 | $3.3B | $539.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BCBPLAB
| Q4 25 | — | — | ||
| Q3 25 | — | $129.4M | ||
| Q2 25 | — | $158.6M | ||
| Q1 25 | — | $150.9M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $210.6M | ||
| Q2 24 | — | $269.8M | ||
| Q1 24 | — | $287.1M |
总债务BCBPLAB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $55.2M | ||
| Q2 24 | — | $55.1M | ||
| Q1 24 | — | $55.0M |
股东权益BCBPLAB
| Q4 25 | $304.3M | — | ||
| Q3 25 | $318.5M | $399.7M | ||
| Q2 25 | $315.7M | $424.5M | ||
| Q1 25 | $314.7M | $454.6M | ||
| Q4 24 | $323.9M | — | ||
| Q3 24 | $328.1M | $489.3M | ||
| Q2 24 | $320.7M | $510.3M | ||
| Q1 24 | $320.1M | $577.3M |
总资产BCBPLAB
| Q4 25 | $3.3B | — | ||
| Q3 25 | $3.4B | $539.6M | ||
| Q2 25 | $3.4B | $557.0M | ||
| Q1 25 | $3.5B | $579.6M | ||
| Q4 24 | $3.6B | — | ||
| Q3 24 | $3.6B | $681.5M | ||
| Q2 24 | $3.8B | $708.7M | ||
| Q1 24 | $3.8B | $777.7M |
负债/权益比BCBPLAB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.11× | ||
| Q2 24 | — | 0.11× | ||
| Q1 24 | — | 0.10× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $35.9M | $-22.2M |
| 自由现金流经营现金流 - 资本支出 | $34.9M | $-23.1M |
| 自由现金流率自由现金流/营收 | 133.3% | -118.1% |
| 资本支出强度资本支出/营收 | 4.0% | 4.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $58.2M | $-111.1M |
8季度趋势，按日历期对齐
经营现金流BCBPLAB
| Q4 25 | $35.9M | — | ||
| Q3 25 | $8.7M | $-22.2M | ||
| Q2 25 | $10.3M | $-20.7M | ||
| Q1 25 | $5.0M | $-30.3M | ||
| Q4 24 | $67.7M | — | ||
| Q3 24 | $43.5M | $-27.9M | ||
| Q2 24 | $8.1M | $-39.0M | ||
| Q1 24 | $8.3M | $-62.5M |
自由现金流BCBPLAB
| Q4 25 | $34.9M | — | ||
| Q3 25 | $8.5M | $-23.1M | ||
| Q2 25 | $10.2M | $-22.6M | ||
| Q1 25 | $4.7M | $-35.3M | ||
| Q4 24 | $66.5M | — | ||
| Q3 24 | $43.4M | $-30.1M | ||
| Q2 24 | $8.1M | $-41.0M | ||
| Q1 24 | $8.1M | $-63.3M |
自由现金流率BCBPLAB
| Q4 25 | 133.3% | — | ||
| Q3 25 | 32.0% | -118.1% | ||
| Q2 25 | 40.4% | -103.6% | ||
| Q1 25 | 19.8% | -86.6% | ||
| Q4 24 | 287.5% | — | ||
| Q3 24 | 166.0% | -136.4% | ||
| Q2 24 | 39.6% | -182.2% | ||
| Q1 24 | 32.3% | -138.9% |
资本支出强度BCBPLAB
| Q4 25 | 4.0% | — | ||
| Q3 25 | 1.1% | 4.5% | ||
| Q2 25 | 0.6% | 8.7% | ||
| Q1 25 | 1.2% | 12.4% | ||
| Q4 24 | 5.3% | — | ||
| Q3 24 | 0.3% | 10.2% | ||
| Q2 24 | 0.2% | 8.6% | ||
| Q1 24 | 0.6% | 1.7% |
现金转化率BCBPLAB
| Q4 25 | — | — | ||
| Q3 25 | 2.05× | — | ||
| Q2 25 | 2.90× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 20.70× | — | ||
| Q3 24 | 6.53× | — | ||
| Q2 24 | 2.88× | — | ||
| Q1 24 | 1.41× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BCBP
暂无分部数据
LAB
| Consumables | $8.7M | 45% |
| Services And Other Revenue | $5.8M | 29% |
| Instruments | $5.1M | 26% |
